MEK-话题@MedSci

#MEK#

68篇内容 | 2183人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1943921, encodeId=068e194392173, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益, objectType=article, longId=206081, objectId=4595206081b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4595206081b2, replyNumber=0, likeNumber=74, createdTime=2021-05-04, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4595206081b2, moduleTitle=复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4595206081b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943924, encodeId=1cf4194392476, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Clin Cancer Res：联合抑制Gα和MEK可明显提高葡萄膜黑色素瘤的治疗效果, objectType=article, longId=206736, objectId=74dc206e362d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74dc206e362d, replyNumber=0, likeNumber=66, createdTime=2021-03-22, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74dc206e362d, moduleTitle=Clin Cancer Res：联合抑制Gα和MEK可明显提高葡萄膜黑色素瘤的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74dc206e362d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943919, encodeId=29c9194391982, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, objectType=article, longId=202790, objectId=00a7202e904b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a7202e904b, replyNumber=0, likeNumber=61, createdTime=2021-05-18, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a7202e904b, moduleTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a7202e904b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943917, encodeId=f8a1194391ecd, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤, objectType=article, longId=201779, objectId=f6f5201e7983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6f5201e7983, replyNumber=0, likeNumber=92, createdTime=2021-08-31, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6f5201e7983, moduleTitle=Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6f5201e7983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943915, encodeId=29eb1943915b8, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle= J Clin Oncol：MEK1/2抑制剂Binimetinib治疗低级别浆液性卵巢癌的疗效, objectType=article, longId=199949, objectId=9c171999498a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c171999498a, replyNumber=0, likeNumber=54, createdTime=2020-09-23, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c171999498a, moduleTitle= J Clin Oncol：MEK1/2抑制剂Binimetinib治疗低级别浆液性卵巢癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c171999498a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943909, encodeId=e0b1194390941, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=J Periodontal Res：LncRNA-01126通过MEK/ERK信号通路抑制人牙周膜细胞迁移, objectType=article, longId=191393, objectId=df5c1913932b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df5c1913932b, replyNumber=0, likeNumber=65, createdTime=2020-10-21, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df5c1913932b, moduleTitle=J Periodontal Res：LncRNA-01126通过MEK/ERK信号通路抑制人牙周膜细胞迁移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df5c1913932b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943908, encodeId=ee62194390895, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Lancet：Bimekizumab治疗活动期银屑病关节炎, objectType=article, longId=187694, objectId=47db18e694e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47db18e694e2, replyNumber=0, likeNumber=67, createdTime=2020-06-13, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47db18e694e2, moduleTitle=Lancet：Bimekizumab治疗活动期银屑病关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47db18e694e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943914, encodeId=41d31943914f3, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=AAD 2020：UCB的bimekizumab在银屑病方面显示出优于Stelara的皮肤清除率, objectType=article, longId=195937, objectId=b9d319593e23, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9d319593e23, replyNumber=0, likeNumber=61, createdTime=2020-09-07, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9d319593e23, moduleTitle=AAD 2020：UCB的bimekizumab在银屑病方面显示出优于Stelara的皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9d319593e23)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943905, encodeId=986019439055f, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, objectType=article, longId=184396, objectId=e1d618439611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1d618439611, replyNumber=0, likeNumber=60, createdTime=2020-01-04, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1d618439611, moduleTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1d618439611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943911, encodeId=a15f194391135, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究, objectType=article, longId=194645, objectId=1e85194645d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e85194645d2, replyNumber=0, likeNumber=56, createdTime=2020-11-18, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e85194645d2, moduleTitle=ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e85194645d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943904, encodeId=280119439044d, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=基于阳性III期结果，EMA已接受将Bratovi和Mektovi联合用于转移性结直肠癌治疗的申请, objectType=article, longId=182599, objectId=86501825990a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86501825990a, replyNumber=0, likeNumber=61, createdTime=2020-03-22, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86501825990a, moduleTitle=基于阳性III期结果，EMA已接受将Bratovi和Mektovi联合用于转移性结直肠癌治疗的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86501825990a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943907, encodeId=f043194390ea7, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=XBiotech将Bermekimab出售给杨森, objectType=article, longId=185515, objectId=11a218551526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11a218551526, replyNumber=0, likeNumber=76, createdTime=2020-05-06, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11a218551526, moduleTitle=XBiotech将Bermekimab出售给杨森, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11a218551526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943906, encodeId=ed4819439063a, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Sci Rep：ALK阳性非小细胞肺癌中双重抑制ALK和MEK抑制细胞生长的机制, objectType=article, longId=184991, objectId=d09c18499171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d09c18499171, replyNumber=0, likeNumber=71, createdTime=2020-01-09, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d09c18499171, moduleTitle=Sci Rep：ALK阳性非小细胞肺癌中双重抑制ALK和MEK抑制细胞生长的机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d09c18499171)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943910, encodeId=2b2f1943910a4, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Ann Rheum Dis：bimekizumab双重中和白介素-17A和17F治疗活动性强直性脊柱炎, objectType=article, longId=191751, objectId=d3f2191e51d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3f2191e51d1, replyNumber=0, likeNumber=105, createdTime=2020-11-09, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3f2191e51d1, moduleTitle=Ann Rheum Dis：bimekizumab双重中和白介素-17A和17F治疗活动性强直性脊柱炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3f2191e51d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943902, encodeId=99c719439022a, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Ann Rheum Dis：对培化舍珠单抗反应不良的类风湿性关节炎中，bimekizumab的疗效和安全性, objectType=article, longId=167998, objectId=9e5216e998c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e5216e998c7, replyNumber=0, likeNumber=76, createdTime=2019-11-29, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e5216e998c7, moduleTitle=Ann Rheum Dis：对培化舍珠单抗反应不良的类风湿性关节炎中，bimekizumab的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e5216e998c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943895, encodeId=27711943895b7, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Prostate Cancer P D：MEK-ERK信号是转移去势抵抗性前列腺癌的治疗靶标, objectType=article, longId=162284, objectId=205b162284e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=205b162284e8, replyNumber=0, likeNumber=75, createdTime=2019-07-29, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=205b162284e8, moduleTitle=Prostate Cancer P D：MEK-ERK信号是转移去势抵抗性前列腺癌的治疗靶标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=205b162284e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943901, encodeId=b8ce194390117, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Braftovi、Mektovi与Erbitux的联合使用可提高转移性结直肠癌患者的生存率, objectType=article, longId=166645, objectId=66b1166645d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66b1166645d2, replyNumber=0, likeNumber=55, createdTime=2020-02-21, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66b1166645d2, moduleTitle=Braftovi、Mektovi与Erbitux的联合使用可提高转移性结直肠癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66b1166645d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943896, encodeId=d5871943896f3, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=NATURE：MEK抑制对组织细胞肿瘤患者的疗效, objectType=article, longId=162456, objectId=189c162456ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=189c162456ec, replyNumber=0, likeNumber=49, createdTime=2019-06-16, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=189c162456ec, moduleTitle=NATURE：MEK抑制对组织细胞肿瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=189c162456ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943898, encodeId=8e531943898ba, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=J Cell Mol Med：Sal B靶向TAZ以促进骨生成并通过MEK-ERK通路减少脂肪形成, objectType=article, longId=163025, objectId=cd3a16302581, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd3a16302581, replyNumber=0, likeNumber=47, createdTime=2019-07-17, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd3a16302581, moduleTitle=J Cell Mol Med：Sal B靶向TAZ以促进骨生成并通过MEK-ERK通路减少脂肪形成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd3a16302581)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943893, encodeId=71fb194389363, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=2019年美国皮肤病学会（AAD）年会：Bimekizumab治疗银屑病患者的长期有效性数据, objectType=article, longId=161608, objectId=5cf41616080b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cf41616080b, replyNumber=0, likeNumber=76, createdTime=2019-12-27, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cf41616080b, moduleTitle=2019年美国皮肤病学会（AAD）年会：Bimekizumab治疗银屑病患者的长期有效性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cf41616080b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

MEK

2020-05-29

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益

2021-05-04

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Clin Cancer Res：联合抑制Gα和MEK可明显提高葡萄膜黑色素瘤的治疗效果

2021-03-22

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐

2021-05-18

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤

2021-08-31

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

J Clin Oncol：MEK1/2抑制剂Binimetinib治疗低级别浆液性卵巢癌的疗效

2020-09-23

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

J Periodontal Res：LncRNA-01126通过MEK/ERK信号通路抑制人牙周膜细胞迁移

2020-10-21

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Lancet：Bimekizumab治疗活动期银屑病关节炎

2020-06-13

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

AAD 2020：UCB的bimekizumab在银屑病方面显示出优于Stelara的皮肤清除率

2020-09-07

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira

2020-01-04

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究

2020-11-18

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

基于阳性III期结果，EMA已接受将Bratovi和Mektovi联合用于转移性结直肠癌治疗的申请

2020-03-22

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

XBiotech将Bermekimab出售给杨森

2020-05-06

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Sci Rep：ALK阳性非小细胞肺癌中双重抑制ALK和MEK抑制细胞生长的机制

2020-01-09

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Ann Rheum Dis：bimekizumab双重中和白介素-17A和17F治疗活动性强直性脊柱炎

2020-11-09

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Ann Rheum Dis：对培化舍珠单抗反应不良的类风湿性关节炎中，bimekizumab的疗效和安全性

2019-11-29

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Prostate Cancer P D：MEK-ERK信号是转移去势抵抗性前列腺癌的治疗靶标

2019-07-29

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Braftovi、Mektovi与Erbitux的联合使用可提高转移性结直肠癌患者的生存率

2020-02-21

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

NATURE：MEK抑制对组织细胞肿瘤患者的疗效

2019-06-16

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

J Cell Mol Med：Sal B靶向TAZ以促进骨生成并通过MEK-ERK通路减少脂肪形成

2019-07-17

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

2019年美国皮肤病学会（AAD）年会：Bimekizumab治疗银屑病患者的长期有效性数据

2019-12-27

科室
- - 订阅+
  - 更多科室
工具
服务